U

UCB Pharma

Biopharmaceuticals for neurology and immunology therapies

Team Leader Maintenance Week-end

Full-Time
No salary listed
Mid
Braine-l'Alleud, Belgium
HybridThe role is based on-site, working Saturday through Monday, 8:00–16:30; 40% of work time is stated as office-based.
General Maintenance & RepairEquipment Maintenance

About the job

Requirements
  • A technical diploma or equivalent experience, with solid expertise in industrial maintenance.
  • Experience in team management or a technical leadership role.
  • Knowledge of regulated environments and GMP standards; pharmaceutical-industry experience is mandatory.
  • Ability to make decisions autonomously and manage priorities.
  • Communication skills in French and technical English.
  • Analytical thinking, results orientation, and ability to solve complex problems.
Responsibilities
  • Supervise a technical team and coordinate maintenance activities for production equipment.
  • Ensure the planning and execution of preventive and corrective maintenance.
  • Manage operational priorities and monitor interventions and performance indicators.
  • Ensure GMP, safety (HSE), and quality compliance in all maintenance activities.
  • Lead continuous improvement, equipment reliability, and a zero-breakdown approach.
  • Collaborate with internal teams and external partners to support technical projects.

About the company

UCB Pharma focuses on developing treatments for severe diseases in neurology and immunology. It discovers, develops, and commercializes novel molecules and generates products aimed at improving patient lives. The company works by researching and developing therapies, integrating patient insights to guide innovation, and investing over a quarter of revenue into scientific research. Its global presence (about 9,000 employees across 40 countries) and €5.3 billion 2023 revenue reflect its scale and commitment to bringing therapies to patients worldwide. UCB differentiates itself by combining direct patient engagement with substantial R&D investment to address unmet needs in neurology and immunology, aiming to transform lives through science and patient care.

Company Size

10,001+

Company Stage

IPO

Headquarters

City of Brussels, Belgium

Founded

1928

Get referred to UCB Pharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue rose 22% to €4.27 billion, with EBITDA margin reaching 40.7%.
  • UCB raised 2026 guidance on July 30, 2026, and lifted Bimzelx peak sales to €7 billion.
  • Georgia’s $2 billion biologics campus, announced March 24, 2026, strengthens U.S. supply and jobs.

What critics are saying

  • Bimzelx concentration intensifies if rivals Cosentyx, Skyrizi, and Icotrokinra erode 2027 growth.
  • August 31, 2026 U.S. pricing concessions and GENEROUS participation compress future launch economics.
  • Nayzilam faces recurring generic pressure; Cipla and Hikma litigation signals durable patent erosion risk.

What makes UCB Pharma unique

  • Bimzelx’s dual IL-17A/F mechanism drove BE BOLD superiority on March 11, 2026.
  • UCB won ATG-201 worldwide rights on March 3, 2026, expanding next-generation immunology.
  • UCB integrates patient-led digital care through DCTx programs, accelerating diagnosis and treatment pathways.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Remote Work Options
  • Paid Vacation
  • PTO/vacation
  • Paid Sick Leave
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match

Growth & Insights and Company News

6 month growth

6%

1 year growth

7%

2 year growth

7%
AD HOC NEWS
Oct 20th, 2026
Umicore stock: Yahoo Finance lists EUR 25.63 average target for Umicore stock.

Umicore stock: Yahoo Finance lists EUR 25.63 average target for Umicore stock. Published on 10/20/2026 at 16:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS First-half adjusted EBITDA rose 33.00 percent to EUR 577.00 million. Umicore stock costs EUR 18.61 on October 20, 2026 versus the EUR 25.63 average target. Target and earnings update. * Yahoo Finance listed a EUR 25.63 average target for Umicore on October 16, 2026. * Adjusted EBITDA rose 33.00 percent to EUR 577.00 million in the first half of 2026. * Umicore stock costs EUR 18.61 at Lang & Schwarz on October 20, 2026 at 4:10 p.m. CEST. * The 52-week range was EUR 14.19 to EUR 26.98 as of October 16, 2026. Umicore stock has a EUR 25.63 average analyst target listed by Yahoo Finance on October 16, 2026, while the target lies 37.72 percent above the EUR 18.61 price. The company also reported adjusted EBITDA of EUR 577.00 million for the first half of 2026, up 33.00 percent from the comparable period. At Lang & Schwarz, the stock was trading at EUR 18.61 on October 20, 2026 at 4:10 p.m. CEST. Discover more Invest in Stocks Track Stock Market Track Investments First-half earnings improved. Umicore said its first-half 2026 performance delivered an earnings uplift across the business and that it upgraded its full-year 2026 adjusted EBITDA outlook. The adjusted EBITDA figure of EUR 577.00 million was 33.00 percent higher than in the first half of 2025. The company operates in materials technology and recycling, with activities spanning battery materials, catalysis, recycling and specialty materials. Stock stays inside annual range. Umicore's 52-week range stood at EUR 14.19 to EUR 26.98 as of October 16, 2026. The price was therefore EUR 7.02 below the yearly high and EUR 4.42 above the yearly low. The same dated market view put the market capitalization at EUR 4.9 billion, the trailing P/E at 9.97 and the year-to-date return at 13.73 percent. Valuation against peers. The Euronext Brussels listing gives Umicore a home-market reference for comparison. Umicore: P/E 9.97, market capitalization EUR 4.9 billion. Solvay (Euronext Brussels, EUR): down 4.98 percent, P/E 2,366.00, market capitalization EUR 2.5 billion. UCB (Euronext Brussels, EUR): up 6.19 percent, P/E 18.87, market capitalization EUR 41.5 billion. What the target means. The EUR 25.63 average target places valuation expectations above the current quote, while the first-half adjusted EBITDA increase provides a concrete operating measure behind the outlook. Umicore's investor-relations page identifies Euronext Brussels as the primary listing and describes the group as a circular materials technology and recycling company. Discover more Source Suppliers Stock price and valuation. Umicore stock was trading at EUR 18.61 at Lang & Schwarz on October 20, 2026 at 4:10 p.m. CEST. Its dated 52-week range and EUR 4.9 billion market capitalization frame the target discussion without turning the analyst figure into a forecast. The further course of trading is shown by the continuously updated real-time quote of Umicore stock. Umicore stock facts. * Company: Umicore S.A. * ISIN: BE0974320526 * WKN: A2H5A3 * Ticker: UMI * Primary exchange: Euronext Brussels * Price Lang & Schwarz (as of October 20, 2026, 4:10 p.m. CEST): EUR 18.61 * Market capitalization: EUR 4.9 billion (as of October 16, 2026) * 52-week range: EUR 14.19-26.98 (as of October 16, 2026) * Sector / Industry: Materials technology and recycling Sponsored Ad Umicore stock: new analysis - 23 October. Discover more Get Recycling Bins Read Company News Find Metal Stocks Fresh Umicore information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | BE0974320526 | UMICORE | boerse | 70374964 | bgmi

Atlanta Standard
Oct 17th, 2026
President Trump visits Georgia, highlights tax relief, job growth, and border security measures.

President Trump visits Georgia, highlights tax relief, job growth, and border security measures. President Trump visited Georgia, citing tax relief, job growth, and border security as key achievements. The administration reported investments from major companies, support for farmers, and a decline in crime rates across the state. 3 days ago Saturday, Oct 17 By ATL Standard October 16 - President Donald J. Trump returned to Georgia, outlining a series of policies and initiatives that he said have delivered tax relief, job creation, and increased security for the state's residents. According to the announcement, Trump's Working Families Tax Cuts have resulted in approximately 1.8 million Georgia seniors paying no federal taxes on Social Security benefits, with the average senior expected to pay zero federal taxes on those benefits. Georgia taxpayers reportedly saw average refunds of $3,169 in 2026, and the tax cuts were said to have safeguarded 198,000 jobs, $36 billion in state GDP, and $18 billion in workers' wages. The state also secured $219 million in first-year funding for rural health investments. Georgia seniors benefited from the new senior deduction, according to the White House, and average refunds were among the highest in the nation, according to Upgraded Points. The statement highlighted a surge in private investment, with companies such as Pirelli, Siemens, and UCB making significant commitments to expand or establish new facilities in Georgia. Pirelli is investing $1.2 billion to expand its Rome facility, creating 1,000 jobs, while Siemens is investing $185 million in Pendergrass, creating 1,400 jobs. UCB is building a $2 billion manufacturing facility in Gwinnett County. Additional investments from companies like Mayville Engineering, DeltaX, ArcelorMittal Building Solutions, and others are expected to bring thousands of new jobs to the state. Georgia is also positioned to benefit from national investments by GE Appliances, Thermo Fisher Scientific, Silver Lake, Anheuser-Busch, and General Dynamics, according to state and company press releases. The administration said it is supporting Georgia families by freezing base rates for Georgia Power customers through 2029, delivering more than $2.8 billion in savings, or $180 per year for the typical residential consumer. Georgia's major utilities have signed the Ratepayer Protection Pledge, ensuring that large data centers, not residential customers, pay for their power and infrastructure needs, according to Georgia Power and the White House. Farmers have received more than $177 million through the Emergency Commodity Assistance Program and over $171 million under a national bridge program for trade disruptions and higher input costs, according to the U.S. Department of Agriculture. On border security, the statement said Trump signed the Laken Riley Act into law, requiring detention of illegal immigrants charged with theft or violence. The administration reported that no illegal aliens have been released from the border into the U.S. interior for 17 consecutive months, and that refugee admissions are down nearly 90% from 2024 levels. Southern border apprehensions in August were 94% lower than the monthly average under the previous administration, and the U.S. recorded negative net migration in 2025 for the first time in 50 years, according to the Department of Homeland Security and Pew Research Center. Crime rates have also declined, with murders in Atlanta dropping 22% last year and homicides down 36% in the first quarter of 2026 compared to the previous year. In DeKalb County, murders fell nearly 30% last year, according to the Major Cities Chiefs Association. The administration said these outcomes reflect ongoing efforts to support law enforcement and implement tough-on-crime policies.

MarketScreener
Oct 16th, 2026
FDA green light for UCB and positive view from DB.

FDA green light for UCB and positive view from DB. Belgian biopharmaceutical group UCB has announced that the US FDA has approved a new administration option for Zilbrysq (zilucoplan), its treatment for generalized myasthenia gravis in adult patients with anti-acetylcholine receptor (AChR) antibodies. Published on 10/16/2026 at 04:00 am EDT MarketScreener.com The authorization covers an auto-injector enabling daily subcutaneous administration by the patient. It is the first device of its kind approved in the United States for this indication. Until now, Zilbrysq had been available as a prefilled syringe. The approval is notably based on a phase 1 study demonstrating the bioequivalence of the two administration methods and on a phase 3b study involving 31 patients. The latter showed that 99.8% of administrations using the auto-injector delivered a full dose of the treatment. Another study, conducted among 100 participants, found that 90% had successfully completed their first injection without prior training. UCB expects to commercialize the new auto-injector in Q1 2027. Meanwhile, Deutsche Bank commented on two third-party surveys covering physicians' reception of the phase 2 data for Tulisokibart in hidradenitis suppurativa (HS) and the latest update on Icotyde in light of the solid launch currently underway at Johnson & Johnson. These two factors are viewed as slight negatives for UCB, although the first is fully consistent with the conclusions most investors drew from the recent conference, while the second reinforces the reasons why investors are apprehensive about the upcoming results for oral Remibrutinib in HS. Nevertheless, Deutsche Bank believes this is more than fully priced in the stock's current valuation; it therefore continues to view the stock as a buy opportunity. The broker therefore has a buy rating on the stock, with a target price of €295. (C) MarketScreener.com - 2026

LQ Ventures
Oct 9th, 2026
Key dermatology treatment trends to watch at EADV 2026.

Key dermatology treatment trends to watch at EADV 2026. Atopic dermatitis: IL-13, IL-18, JAK inhibitors and emerging therapies. IL-13, IL-18, IL-4Rα, JAK and regulatory T-cell approaches will compete on durability, difficult-to-treat sites, dosing and treatment simplicity. Hidradenitis suppurativa: tulisokibart, lutikizumab and abdakibart. Tulisokibart, lutikizumab and abdakibart will test whether targeting inflammatory and fibrotic biology translates into meaningful differentiation in tunnels, scarring and deeper disease. Alopecia areata: bempikibart, ritlecitinib and baricitinib. Bempikibart, ritlecitinib and baricitinib data will shift attention toward long-term disease control, treatment-free response and adolescent treatment. Psoriasis: icotrokinra, zasocitinib and oral treatment competition. Two-year icotrokinra data and zasocitinib versus deucravacitinib could raise expectations for oral psoriasis therapies beyond convenience alone. Competitor and industry signals at EADV 2026. Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly and UCB: dermatology competition. Pfizer, Johnson & Johnson, Novartis, AbbVie, Lilly, UCB and other companies are emphasizing earlier intervention, sustained disease control and more individualized systemic treatment strategies. Emerging dermatology pipeline: new mechanisms and clinical data. Oturkibart, zumilokibart/APG777, bempikibart, daxdilimab, lunsekimig, tulisokibart and MG-K10 add new mechanisms and late-breaking datasets to watch. Artificial intelligence and machine learning at EADV 2026. AI in dermatology: diagnosis, melanoma risk prediction and dermoscopy. Sessions will focus on AI-supported diagnosis, melanoma risk prediction, dermoscopy, teledermatology and image-based assessment rather than drug discovery. Clinical integration: MELAPRED, Vision transformers and 3D imaging. MELAPRED, Vision Transformer dermoscopy and 3D total-body photography will test whether AI can add value alongside dermatologist assessment. What LucidQuest Ventures LTD is watching after EADV 2026. * Whether emerging hidradenitis suppurativa mechanisms translate into clinically meaningful differentiation. * Whether oral psoriasis therapies deliver deeper, durable disease control at high-impact sites. * Whether longer-term clinical datasets establish treatment durability as a stronger competitive differentiator. * Whether AI evidence is strong enough to support routine dermatology diagnosis, risk assessment and monitoring. Download the EADV 2026 preview report. Download LucidQuest's EADV 2026 preview report for deeper analysis of emerging dermatology treatments, clinical developments and competitive signals. Build your schedule around the sessions that matter most. Contact LucidQuest Ventures LTD for end-to-end conference coverage.

Georgia Public Broadcasting
Oct 9th, 2026
GPB evening headlines for October 9, 2026.

GPB evening headlines for October 9, 2026. October 9, 2026 3:54 PM Authorities are urging Georgians to prepare as Hurricane Isaias is expected to bring heavy rain and damaging winds. Democratic U.S. Sen. Jon Ossoff and his Republican challenger Mike Collins faced off in a live televised debate. Belgian pharmaceutical maker UCB broke ground today on a $2 billion drug manufacturing plant in Gwinnett County. Support local journalism. GPB believes that everyone should have access to trustworthy, fact-based stories that connect them to their community and outward to the wider world. Your donation will help Georgia Public Broadcasting in its efforts to unite and uplift Georgia. GPB is vital. Always educational, essential, inspiring and grounding. So happy to be a supporter. - Kelli D., Athens, Ga. The latest from GPB News Support quality journalism. GPB is committed to bringing you comprehensive news coverage from Georgia, across the country and around the world. Your support makes this possible. Please consider making a gift today to support this vital public service.